{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-033767","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.531002+00:00","generated_at":"2026-05-17T08:33:32.048238+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant reports ~80% durability and ~50% ATD-free remission in Graves' disease data","bullets":["Of 21 patients in 6-month off-treatment follow-up, ~80% (17/21) maintained normal thyroid function.","~50% of responders (8/17) achieved anti-thyroid drug-free remission after 6 months off batoclimab.","Two registrational trials for IMVT-1402 in Graves' disease are enrolling; topline data expected 2027.","Safety consistent with prior batoclimab studies; first potential disease-modifying therapy for uncontrolled GD.","Roivant and Immunovant to host investor call Sept 3, 2025 at 4:30 p.m. EDT to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-033767","json":"https://secwatch.observer/filing/0001140361-25-033767.json","markdown":"https://secwatch.observer/filing/0001140361-25-033767.md","text":"https://secwatch.observer/filing/0001140361-25-033767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/0001140361-25-033767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/ef20055076_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:33:32.048238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}